Numinus Wellness To Undertake Phase 1 Study Of Psilocybin Extract
Numinus Wellness (TSXV: NUMI) is undertaking further studies of its psilocybin products. The company this morning announced a partnership with KGK Science, whereby it will begin studying a psilocybin extract produced in its lab.
The clinical trial is to study the safety and psychoactive properties of a Psilocybe mushroom product that has been extracted and formulated by the study. Classified as a phase 1 trial, the trial is to consist of 14 volunteers that will be used to assess the safety and efficacy of such a product, which will then be used in further trials, or under compassionate-use guidelines.
The study is expected to create IP for the company while also enabling further studies to be conducted in the future.
Numinus Wellness last traded at $1.08 on the TSX Venture.
Information for this briefing was found via Sedar and Numinus Wellness. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.
